Asahiro Morishita

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 326 publications

Teachable Moments in Alcohol-Related Diseases: A Practical Framework for Promoting Abstinence in General Internal Medicine.

Teachable Moments in Alcohol-Related Diseases: A Practical Framework for Promoting Abstinence in General Internal Medicine.

Journal: Internal medicine (Tokyo, Japan)

Published: September 02, 2026

ALT Reduction Following Pemafibrate Treatment in MASLD and MetALD with Dyslipidemia: Associations with the Baseline Liver Enzyme Levels.

ALT Reduction Following Pemafibrate Treatment in MASLD and MetALD with Dyslipidemia: Associations with the Baseline Liver Enzyme Levels.

Journal: Internal medicine (Tokyo, Japan)

Published: July 20, 2026

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Copper-deficiency anemia and neutropenia during zinc maintenance therapy for Wilson disease associated with persistent strict dietary copper restriction.

Copper-deficiency anemia and neutropenia during zinc maintenance therapy for Wilson disease associated with persistent strict dietary copper restriction.

Journal: Clinical journal of gastroenterology

Published: April 29, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Constipation in Older Adults: Pathophysiology, Clinical Impact, and Management Strategies.

Constipation in Older Adults: Pathophysiology, Clinical Impact, and Management Strategies.

Journal: Geriatrics (Basel, Switzerland)

Published: February 22, 2026

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 30, 2026

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Journal: Hepatology (Baltimore, Md.)

Published: January 27, 2026

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal: Journal of gastroenterology and hepatology

Published: January 19, 2026

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 13, 2026

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 12, 2026

Showing 1-12 of 326

Last Updated: 09/26/2026